跳至主要内容
临床试验/NCT06045377
NCT06045377已完成不适用

Effect of a Nutraceutical, Containing Red Yeast Rice and Polycosanols (Armolipid), on Lipid Profile in Children With Moderate and Severe Hypercholesterolemia.

Athens General Children's Hospital "Pan. & Aglaia Kyriakou"1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2020年1月20日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
90
试验地点
1
主要终点
Levels of LDL-C serum levels

研究概览

简要总结

Data concerning the effectiveness od nutraceuticals in children with dyslipidemia are lacking. The aim of the present study was to evaluate the efficacy and safety of the long-term use of a dietary supplement containing red yeast rice (RYR), combined with other natural compounds, in children and adolescents with hypercholesterolemia.

A nutraceutical, containing RYR, polycosanols, coenzyme Q10, astaxanthin and folic acid (commercial name: Armolipid), was administered once-daily in 84 children/adolescents with moderate or severe hypercholesterolemia.

详细描述

This is a prospective single center cohort study conducted at Outpatient Lipid Unit of 2nd Department of Pediatrics of the National and Kapodistrian University of Athens at the "Panagiotis & Aglaia Kyriakou" Children's Hospital in Greece. The study complies with the Declaration of Helsinki and the protocol was reviewed and approved by the appropriate ethical committee. Parental informed written consent was obtained prior to enrollment.

Study population: Ninety children and adolescents, aged 7 to 16 years, with primary dyslipidemia.

All participants had a positive family history for hypercholesterolemia (LDL > 95th percentile) and most of them had a positive family history for premature CVD (<55 years for males and <60 years for females) in first or/and second-degree relatives. Eleven of them had a genetically confirmed diagnosis of HeFH, while the rest had a probable or positive HeFH according to the Dutch Lipid Clinic Network criteria. None of them had moderate or significant hypertriglyceridemia, even those with increased body mass index (BMI).

All children followed a low saturated fat and low cholesterol diet by a trained dietician and had moderate or intense physical activity, for at least 6 months before the participation in the study. In addition, during the last 6 months, 19 of them consumed 1.5 - 2.5g of plant sterols daily in the form of a yogurt drink or spread. Lifestyle and eating habits were maintained throughout the study.

A nutraceutical containing five natural substances formulated as a tablet with the commercial name Armolipid (Rottapharm S.p.A., Monza, Italia), was recommended in all participants. Every tablet contained 200 mg red yeast rice (RYR) extract equivalent to 3 mg of monacolin K, 10 mg policosanols, 0.2 mg folic acid, 2.0 mg coenzyme Q10 and 0.5 mg astaxanthin, and was citrinin-free. It was administered once-daily with lunch.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
7 Years 至 16 Years(Child)
性别
All
接受健康志愿者
是

入选标准

  • •LDL-C >150 mg/dl in more than two measurements, after therapeutic lifestyle changes for at least 6 months.

排除标准

  • •Secondary hypercholesterolemia
  • •Presence of any chronic disease or growth and developmental disorders
  • •Abnormal liver, kidney or thyroid function
  • •Prior use of hypolipidemic or other medication, at least 6 months before participation in the study.

研究组 & 干预措施

Armolipid

Experimental

One tablet of Armolipid (Rottapharm S.p.A., Monza, Italia), containing 200 mg red yeast rice, 10 mg policosanols, 0.2 mg folic acid, 2.0 mg coenzyme Q10 and 0.5 mg astaxanthin was administered once-daily with lunch.

Clinical and laboratory evaluation took place before and 6 (IQR: 5-8) and 16 (IQR: 11-19.7) months after treatment.

干预措施: Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia (Dietary Supplement)

结局指标

主要结局

Levels of LDL-C serum levels

时间窗: Laboratory evaluation before and 6 and 16 months after treatment

LDL-C levels were evaluated in serum, after an overnight fast.

次要结局

  • Improvement of other than LDL-C parameters of lipid profile, as well as the evaluation of hepatic and muscle enzymes elevation.(Laboratory evaluation before and 6 and 16 months after treatment)

研究者

发起方
Athens General Children's Hospital "Pan. & Aglaia Kyriakou"
申办方类型
Other
责任方
Principal Investigator
主要研究者

Achilleas Attilakos

Assoc. Prof. of Pediatrics

Athens General Children's Hospital "Pan. & Aglaia Kyriakou"

研究点 (1)

Loading locations...

相似试验

Effect of Armolipid on Lipid Profile in Children... | 临床试验